Skip to main content

Main menu

  • About Us
    • Leadership
    • Our Team
    • Vision, Mission and Values
    • Health and Economic Impact
    • Research Impact Video
    • Strategic Plan
  • Our Research
    • Research Focus
      • Brain Health
      • Cancer
      • Digital Health and Artificial Intelligence
      • Heart Health
      • Healthy Aging and Mobility
      • Immune System
      • Injury and Rehabilitation
      • Lung Health
      • Mental Health and Substance Use
    • Research Centres and Programs
      • BC Centre on Substance Use
      • Centre for Aging SMART
      • Centre for Clinical Epidemiology and Evaluation
      • Centre for Lung Health
      • Dilawri Cardiovascular Institute
      • Djavad Mowafaghian Centre for Brain Health
      • Immunity and Infection Research Centre
      • International Collaboration On Repair Discoveries
      • M. H. Mohseni Institute of Urologic Sciences
      • Ovarian Cancer Research Centre
      • Community Research Program
      • Emergency Medicine Research Program
      • Hematology Research Program
      • Skin Research Program
      • Other Research Focus Areas
    • News and Stories
    • Researcher Directory
    • Events and Workshops
  • Research Services
    • New to VCHRI
      • Working at VCHRI
      • Regulations and Training
      • Membership with VCHRI
      • Learning and Development
    • Starting Your Project
      • Research Facilitation
      • Awards and Funding
      • Grant Management
      • Operational Approval
      • CST Cerner
    • Developing Your Project
      • Clinical Trials Administration
      • Clinical Research Unit
      • Research Privacy
      • Financial Policies and Procedures
    • Additional Support
      • Indigenous Health Research Unit
      • VCH-VCHRI AI Hub
      • Communications and Media Relations
      • Study Recruitment Support
      • Innovation and Industry Partnership
    • Internal Awards
    • Clinical Research
    • Indigenous Research
  • Participate in Research
    • Reasons to Participate
    • Participant Stories
    • Find a Study
    • Recruitment Support

User menu

  • Log in

Breadcrumb

  1. Home
  2. Participate in Research
  3. Brain and Nerves

Brain and Nerves

Recruiting

Examining decision making in Parkinson's Disease

The purpose of this study is to examine the effects of Parkinson's medication on decision making and risk taking in healthy control participants. 

Status
Recruiting
Principal Investigator
Jason Barton
Body Locations and Systems
Parkinson's Disease
Area
Vancouver
Age
50 and above

MINT-01 (A Medium Chain Triglyceride INTervention for Alzheimer Disease (A MINT for AD Study)

This study will test the safety and tolerability of a medium chain triglyceride (MCT) supplement in those with Alzheimer Disease (AD). 

Recruitment Poster

Status
Recruiting
Principal Investigator
Haakon Nygaard
Body Locations and Systems
Alzheimer's Disease
Area
Vancouver
Age
50-90

P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA (Toca5)

This is a multicenter, randomized, open-label phase 2/3 study of Toca 511 and Toca FC versus standard of care that comprises Investigator's choice of single agent chemotherapy (lomustine or temozolomide) or bevacizumab administered to subjects undergoing resection for first or second recurrence (including this recurrence) of GBM or AA. Subjects meeting all of the inclusion and none of the exclusion criteria will be randomized prior to surgery in a 1:1 ratio to receive either Toca 511 and Toca FC (Experimental arm, Arm T) or control treatment with one option of standard of care (Arm SOC).

Status
Recruiting
Body Locations and Systems
Tumour
Area
Vancouver
Age
18-75

Contrasting Group Therapy Methods for Psychosis (MCT)

Current Canadian Clinical Practice guidelines emphasize the need for effective psychosocial adjuncts to pharmacotherapy for schizophrenia (Canadian Psychiatric Association 2005). This randomized control trial seeks to contribute to the body of evidence supporting psychosocial treatments by assessing the effectiveness of metacognitive training (MCT) and cognitive remediation (CR) at treating the persistent positive and cognitive symptoms of schizophrenia.

Status
Recruiting
Principal Investigator
Todd Woodward
Body Locations and Systems
Brain
Area
Vancouver
Age
19-60

Telmisartan vs. Perindopril in Hypertensive Mild-Moderate Alzheimer's Disease Patients (SARTAN-AD)

The purpose of this project is to conduct a proof of concept study in patients with probable Alzheimer's Disease who have mild to moderate hypertension, in order to determine if there is less global brain atrophy over one year, as measured by ventricular enlargement as a primary outcome measure, when patients are randomized to treatment with an angiotensin receptor blocker compared to an Angiotensin Converting Enzyme inhibitor (ACEI).

recruitment poster

Status
Recruiting
Principal Investigator
Ging-Yuek Robin Hsiung
Body Locations and Systems
High Blood Pressure
Alzheimer's Disease
Area
Vancouver
Age
50 and above

Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)

This study will be investigating the effects of fesoterodine on autonomic dysreflexia (AD) in patients with spinal cord injuries (SCI). The goal of the study is to examine the effect of increasing daily use of fesoterodine on episodes of high blood pressure triggered by urinary bladder contractions.

Recruitment Poster

Status
Recruiting
Principal Investigator
Andrei Krassioukov
Body Locations and Systems
High Blood Pressure
Spinal Cord Injury
Area
Vancouver
Age
18-55

Characterising Arm Recovery in People With Severe Stroke (CARPSS)

The main goal of this program of research is to advance our understanding of how the severely damaged brain changes over the first 12-months post stroke. The investigators will determine 'who recovers', 'who does not recover', and 'why'

Status
Recruiting
Principal Investigator
Lara Boyd
Body Locations and Systems
Stroke
Area
Vancouver
Age
18-90

A Randomized Controlled Trial of TNK-tPA Versus Standard of Care for Minor Ischemic Stroke With Proven Occlusion (TEMPO-2)

This trial will enroll patients that have been diagnosed with a transient ischemic attack (TIA) or minor stroke that has occurred within the past 12 hours. Anyone diagnosed with a minor stroke faces the possibility of long-term disability and even death, regardless of treatment. Stroke symptoms such as weakness, difficulty speaking and paralysis may improve or worsen over the hours or days immediately following a stroke. TEMPO-2 is a minor stroke trial for patients presenting within 12 hours of their symptom onset. Patients will be randomized to TNK-tPA or standard of care.

Status
Recruiting
Principal Investigator
Thalia Field
Body Locations and Systems
Stroke
Stroke
Area
Vancouver
Age
18 and above

Developing a risk assessment tool for discriminating social cognition deficits in dementia from that of depression

To look at the differences in "social cognition"- the ability to look at the interpret the social world and put yourself in someone else's shoes - between people with depression, people with frontotemporal dementia and healthy controls.

Status
Recruiting
Principal Investigator
Howard Feldman
Body Locations and Systems
Dementia
Depression
Area
Vancouver
Age
40-80

Aneurysmal Subarachnoid Hemorrhage: Red Blood Cell Transfusion and Outcome (SAHaRA Pilot)

The purpose of this study is to determine the feasibility of conducting a large trial examining the effect on clinical outcome of a liberal red blood cell (RBC) transfusion strategy compared to a restrictive strategy (usual care) in patients with aneurysmal subarachnoid hemorrhage (SAH)

Status
Recruiting
Principal Investigator
Donald Griesdale
Body Locations and Systems
Aneurysm
Blood Transfusion and Donation
Area
Vancouver
Age
18 and above

Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in Atrial Fibrillation (BRAIN-AF)

This is a prospective, multicenter, randomized, double-blinded clinical trial exploring the efficacy and safety of rivaroxaban as compared to acetylsalicylic acid in reducing stroke, transient ischemic attack (TIA) and neurocognitive decline, in subjects with non-valvular AF and with low risk of stroke.

Status
Recruiting
Principal Investigator
Anthony Fung
Body Locations and Systems
Stroke
Atrial Fibrillation
Area
Vancouver
Age
30-60

A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders

To compare the efficacy of MEDI-551 versus placebo in reducing the risk of an NMO/NMOSD attack in subjects with NMO/NMOSD.

Status
Recruiting
Principal Investigator
Robert Carruthers
Body Locations and Systems
Neurologic Diseases
Vision Impairment and Blindness
Area
Vancouver
Age
18 and above

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have, or are at risk of having an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers.
This study also offers an observational component collecting cognitive assessment data until the availability of an enrolling drug treatment group, referred to as cognitive run-in (CRI).

 

Status
Recruiting
Principal Investigator
Ging-Yuek Robin Hsiung
Body Locations and Systems
Alzheimer's Disease
Neurologic Diseases
Dementia
Area
Vancouver
Age
18-80

Low-dose vs. Normal-dose Psychostimulants on Executive Functions in Children With ADHD

This double-blind crossover study aims to compare cognitive performance (e.g., working memory, selective attention and cognitive flexibility) of children ages 6-18 years diagnosed with ADHD of the combined type (ADHD-C) or inattentive-type (ADHD-IA) and currently on > 20 mg/day of psychostimulants (psychostimulants) on: a) their current dose of psychostimulants, vs. b) a lower-dose of psychostimulants (half of their current dose).

Status
Recruiting
Principal Investigator
Adele Diamond
Body Locations and Systems
Brain
Area
Vancouver
Age
6-18

The Music Study in Refractory Psychosis (MARS)

The perception of music requires coordinated neural activities in distributed multi-functional centers across both hemispheres. The association between musical abilities and other general cognitive functions have been studied in several populations with inconsistent results.

Status
Recruiting
Body Locations and Systems
Brain
Area
Vancouver
Age
18 and above

Determining Optimal Post-Stroke Exercise (DOSE)

The investigators will conduct a proof-of-concept study to provide preliminary evidence of efficacy of physical exercise dose on ambulatory function in adults undergoing sub-acute stroke rehabilitation.

Status
Recruiting
Principal Investigator
Janice Eng
Body Locations and Systems
Stroke
Area
Vancouver
Age
19 and above

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL)

Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials.

Status
Recruiting
Principal Investigator
Ian R.A. Mackenzie
Body Locations and Systems
Neurologic Diseases
Area
Vancouver
Age
18-85

Serial Comparisons of Abdominal and Neurological MRI Scans (SCANMRI)

The purpose of this study is to compare abdominal weight gain and fat distribution to changes in brain morphology in people taking antipsychotic medications.

Status
Recruiting
Body Locations and Systems
Brain
Area
Vancouver
Age
12 and above

Canadian Fabry Disease Initiative (CFDI) Enzyme Replacement Therapy (ERT) Study

CFDI STUDY with ENZYME REPLACEMENT THERAPY (ERT)

Fabry disease is a rare, inherited, genetic condition due to a deficiency of an enzyme called alpha-galactosidase A. This enzyme deficiency causes the small blood vessels to accumulate a substance called glycolipid. Without sufficient levels of the enzyme, alpha-galactosidase A, persons with Fabry Disease develop severe neuropathic pain, kidney disease, heart disease, stroke and/or premature death; often before the age of 60.

Status
Recruiting
Principal Investigator
Sandra Sirrs
Body Locations and Systems
Brain
Area
Vancouver
Age
5-85

Coping styles and their correlation to outcomes in Parkinson's Disease

Parkinson's Disease (PD) is a progressive neurodegenerative disorder without a cure. While the search for a cure continues, there is a growing interest in psychiological approaches to manage distress in PD. The main objective of this study is to investigate various clinical outcomes in PD associated with different coping styles. Findings from this study will form the basis for projects aimed at designing interventions to foster beneficial coping styles and studies into the neural underpinnings of coping. 

Status
Recruiting
Principal Investigator
Silke Appel-Cresswell
Body Locations and Systems
Parkinson's Disease
Area
Vancouver
Age
18 and above

Pagination

  • Previous page
  • …
  • Page 2
  • Page 3
  • Current page 4
  • Page 5
  • Page 6
  • …
  • Next page
Subscribe to Brain and Nerves

Get updates!

Join our newsletter mailing list to stay up to date on features and releases.

Subscribe

Quick Links

  • News and Stories
  • Careers
  • Events
  • Media Enquiries

Follow Us

  • LinkedIn
  • X
  • YouTube

© 2025 VCHRI. All rights reserved.

  • Contact
  • Privacy Policy